7 results about "Underlying disease" patented technology

The invention relates to the technical field of brain disease diagnosis and treatment decision reasoning, in particular to a diagnosis and treatment decision reasoning method fusing LLM and a knowledge graph, which comprises the following steps of: extracting a plurality of standard entities at least comprising symptom entities and case entities in brain disease cases by adopting a language model; taking the symptom entity and the case entity as a plurality of suspected diseases and candidate diseases corresponding to the retrieval knowledge graph; calculating the disease similarity between each suspected disease and each candidate disease; defining candidate diseases of which the disease similarity is greater than or equal to a similarity threshold value, and forming a potential disease set by taking all suspected diseases as potential diseases; setting each potential disease in the potential disease set as a starting node, and constructing a directed correlation sub-graph based on the knowledge graph; and defining a plurality of examination means corresponding to each potential disease in the directed correlation subgraph as evaluation means, and screening the evaluation means with effective identification capability to construct an evaluation means set.

The invention discloses a septicopyemia early warning method, device and system and a storage medium. The septicopyemia early warning method comprises the following steps: acquiring patient observation data of a target patient under continuous time steps; acquiring a hidden state vector of the target patient under the current time step and a corresponding individualized baseline reference interval; generating an anti-fact observation result in each anti-fact disease cause scene; calculating a disease cause attribution vector and an infection specific residual error of the target patient under the current time step; calculating a septicopyemia event window risk value of the target patient in a preset time window; and outputting risk prompt information of the target patient in the current time step. By adopting the technical scheme of the invention, the problem that the existing early warning method is difficult to distinguish the causes of diseases among patients with multiple basic diseases is solved.

An object of the system according to the embodiment is to unitarily analyze a plurality of symptoms of an individual and specify the possibility of a potential disease.SOLUTION: A system includes a symptom input part, a symptom analysis part, and a database collation part. The symptom input unit collects symptoms input by a user. The symptom analysis unit analyzes the symptoms collected by the symptom input unit. The database collation unit collates the symptom analyzed by the symptom analysis unit with the medical database.SELECTED DRAWING: Figure 1

The application discloses a common animal disease early warning method and system based on breeding environment detection data, and relates to the technical field of animal disease early warning. The method comprises the following steps: interacting with a target breeding environment, obtaining breeding environment detection data and neighborhood environment data; determining breeding object information of the target breeding environment, calling a pre-constructed disease classifier for qualitative classification analysis, and outputting a result as a potential disease set; determining a risk accumulation rate set of M environment indexes in the breeding environment detection data for the potential disease set according to historical disease data; generating predicted environment sequence data of the target breeding environment according to the neighborhood environment data and the breeding environment detection data, performing risk accumulation calculation on the potential disease set, and obtaining an accumulated disease risk of each potential disease; generating an animal disease early warning report based on the multiple accumulated disease risks, and performing early warning response. The application solves the technical problem of inaccurate animal disease early warning in the prior art.

This invention discloses a traditional Chinese medicine composition for the prevention, mitigation, or treatment of Alzheimer's disease, comprising 8-12 parts of Cistanche deserticola, 8-12 parts of Polygonatum sibiricum, 8-12 parts of Panax ginseng, 12-18 parts of Astragalus membranaceus, 12-18 parts of Angelica sinensis, 12-18 parts of Ligustrum lucidum, 8-12 parts of Salvia miltiorrhiza, and 8-10 parts of Panax notoginseng, all by weight. The traditional Chinese medicine composition of this invention significantly improves Alzheimer's disease-related symptoms in a mouse model of Alzheimer's disease, including the novel object recognition index, Y-maze spatial cognition index, water maze activity index, number and distribution of Nissl bodies in neurons, and β-amyloid protein deposition. It is expected to effectively prevent, mitigate, or improve different stages of Alzheimer's disease and its related complications and underlying diseases.

Reanalysis of the SIMPLIFY 1 and 2 trials data indicates MMB is effective in JAKi-naïve patients and in second line therapy to RUX, providing benefits of reducing enlarged spleens, improving myelofibrosis-related symptoms, and increasing transfusion independence in patient at risk for thrombocytopenia from the underlying disease and RUX therapy. Accordingly, methods of treating myeloproliferative neoplasms (MPN) such as myelofibrosis are described. The methods can include administering a therapeutically effective amount of momelotinib or a pharmaceutically acceptable salt thereof to a subject identified as having (i) myelofibrosis and (ii) a platelet count of less than 150×109 / L. Also described are methods including administering to a subject with myelofibrosis a therapeutically effective stable dose of momelotinib or a pharmaceutically acceptable salt thereof, for a period of a plurality of weeks, where the subject is assessed as maintaining a platelet count above a predetermined threshold platelet count during the period.

Reanalysis of the SIMPLIFY 1 and 2 trials data indicates MMB is effective in JAKi-naïve patients and in second line therapy to RUX, providing benefits of reducing enlarged spleens, improving myelofibrosis-related symptoms, and increasing transfusion independence in patient at risk for thrombocytopenia from the underlying disease and RUX therapy. Accordingly, methods of treating myeloproliferative neoplasms (MPN) such as myelofibrosis are described. The methods can include administering a therapeutically effective amount of momelotinib or a pharmaceutically acceptable salt thereof to a subject identified as having (i) myelofibrosis and (ii) a platelet count of less than 150×109 / L. Also described are methods including administering to a subject with myelofibrosis a therapeutically effective stable dose of momelotinib or a pharmaceutically acceptable salt thereof, for a period of a plurality of weeks, where the subject is assessed as maintaining a platelet count above a predetermined threshold platelet count during the period.